168 related articles for article (PubMed ID: 9547998)
1. Targeted antibodies in the treatment of lymphomas.
Falini B; Terenzi A; Liso A; Flenghi L; Solinas A; Pasqualucci L
Cancer Surv; 1997; 30():295-309. PubMed ID: 9547998
[TBL] [Abstract][Full Text] [Related]
2. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective.
Press OW
Semin Oncol; 2003 Apr; 30(2 Suppl 4):10-21. PubMed ID: 12728403
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. [Use of antibodies or their fragments for the treatment of tumors].
Douillard JY; Chatal JF
Bull Cancer; 1998 Nov; 85(11):951-9. PubMed ID: 9951422
[TBL] [Abstract][Full Text] [Related]
6. Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
Byers VS; Baldwin RW
Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344
[TBL] [Abstract][Full Text] [Related]
7. The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice.
Wei BR; Ghetie MA; Vitetta ES
Clin Cancer Res; 2000 Feb; 6(2):631-42. PubMed ID: 10690549
[TBL] [Abstract][Full Text] [Related]
8. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
9. Antibody-targeted therapy for low-grade lymphoma.
Vose JM
Semin Hematol; 1999 Oct; 36(4 Suppl 6):15-20. PubMed ID: 10530712
[TBL] [Abstract][Full Text] [Related]
10. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates.
Press OW
Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S19-26. PubMed ID: 9672771
[TBL] [Abstract][Full Text] [Related]
11. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
Schnell R; Staak O; Borchmann P; Schwartz C; Matthey B; Hansen H; Schindler J; Ghetie V; Vitetta ES; Diehl V; Engert A
Clin Cancer Res; 2002 Jun; 8(6):1779-86. PubMed ID: 12060617
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.
Ng B; Kramer E; Liebes L; Wasserheit C; Hochster H; Blank E; Ceriani R; Furmanski P
Cancer Res; 2001 Apr; 61(7):2996-3001. PubMed ID: 11306478
[TBL] [Abstract][Full Text] [Related]
13. Antibodies in the therapy of colon cancer.
Welt S; Ritter G
Semin Oncol; 1999 Dec; 26(6):683-90. PubMed ID: 10606261
[TBL] [Abstract][Full Text] [Related]
14. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].
Chiron MF
Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366
[TBL] [Abstract][Full Text] [Related]
15. The development of immunotoxins for the therapy of cancer, AIDS, and immune dysfunctions.
Vitetta ES
Princess Takamatsu Symp; 1988; 19():333-40. PubMed ID: 3077626
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ
Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
Maloney DG
J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
[TBL] [Abstract][Full Text] [Related]
19. [Recent progress in the treatment of malignant lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1213-35. PubMed ID: 11579632
[TBL] [Abstract][Full Text] [Related]
20. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
